Oklo (NYSE:OKLO | OKLO Price Prediction) has been one of the most volatile bets on the AI nuclear thesis. After a punishing pullback, our model sees room to run. Shares closed at $44.13 on July 21, 2026, well off the $193.84 52-week high.
Our 24/7 Wall St. price target for Oklo is $97.74, implying 121.49% upside over the next 12 months. Our call is buy with moderate (50%) confidence.
| Metric | Value |
|---|---|
| Current Price | $44.13 |
| 24/7 Wall St. Price Target | $97.74 |
| Upside | 121.49% |
| Recommendation | BUY |
| Confidence Level | 50% |
From a $171 Peak to a $44 Reset
Oklo shares are down 38.5% year to date, 27.86% over the past month, and 29.4% over the past year. After peaking near $171.56 in October 2025, the stock now trades only 11% above the 52-week low of $39.53.
Recent catalysts have been constructive. On July 21, Oklo was selected alongside X-Energy for a $200 million Trump administration program to accelerate nuclear reactors for AI data centers, with tech partners including Microsoft and NVIDIA.
The DOE approved the Documented Safety Analysis for the Groves Isotope Test Reactor in Texas in July, and Cathie Wood’s ARK Invest added 100,854 shares to ARKQ on July 14.
The Case for $170 and Higher
Bulls call Oklo the best-positioned pure-play in advanced nuclear. The customer pipeline sits near 14 GW, anchored by a 12 GW master agreement with Switch through 2044 and a 500 MW Equinix LOI backed by a $25 million pre-payment. Management targets first commercial power at Idaho National Laboratory by late 2027, with Atomic Alchemy radioisotope revenue possible as early as 2026.
Goldman Sachs projects AI-driven data center power demand rising 165% by 2030, and the NRC proposed cutting service fees for advanced reactor applicants by nearly 55%. Texas Capital Securities carries a $93 Buy and B.Riley a $92 Buy. The bull-case scenario reaches $169.92 by July 2027, a 285% gain, if licensing and hyperscaler deals convert on schedule.
What Could Go Wrong
Oklo generated $0 in revenue in FY2024 on a net loss of $73.62 million, and customer agreements remain largely non-binding LOIs. Full NRC design approval for Aurora is pending, and reactor construction timelines historically slip. Short interest recently hit $1.65 billion, or 19.29% of float.
The widened R&D spend of $26.71 million in FY2024, nearly triple YoY, reflects deliberate investment in Aurora, and Oklo’s $2.54 billion cash position gives management years of runway. The bear-case scenario lands at $79.09, comfortably above today’s price.
How Oklo Stacks Up Against NuScale and Constellation
NuScale Power (NYSE:SMR) is the closest pre-revenue SMR pure-play and the only developer holding NRC design approval. NuScale’s market cap sits at roughly $3.01 billion, less than half of Oklo’s $7.22 billion, and recent quarterly revenue remains minimal versus consensus. Investors are paying a premium for Oklo tied to its data center customer roster and sodium-cooled Aurora design.
Constellation Energy (NASDAQ:CEG) offers the profitability counterpoint. The largest US nuclear operator remains solidly profitable at utility scale. Against SMR, the $97.74 target looks reasonable. Against CEG, Oklo carries a large execution premium that only commercial startup can justify.
Our Verdict on the Reset
Our 24/7 Wall St. price target for Oklo is $97.74, a buy with 50% confidence. Shares trade only 11% above the 52-week low even as regulatory milestones and federal AI-nuclear partnerships accelerate.
The bull thesis rests on Oklo converting its 14 GW pipeline into binding contracts and hitting the late-2027 Idaho startup. Investors requiring commercial revenue before committing capital face an 18 to 24 month wait.
Oklo Price Prediction 2026-2030
| Year | 24/7 Wall St. Price Target |
|---|---|
| 2026 | $61 |
| 2027 | $98 |
| 2028 | $138 |
| 2029 | $196 |
| 2030 | $277 |
These projections assume Oklo executes on the Idaho commercial startup, secures full NRC design approval, and converts LOIs into binding revenue.
Contact [email protected] for any questions or corrections.